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INTRODUCTION
Caries and periodontal disease remain the most common oral infectious diseases in humans, despite the
use of antibiotics, fluorides and other oral health agents. Antibiotic resistance acquired by oral micro-

organisms amplifies the need to develop innovative strategies for controlling plaque-related oral
infections.1 Antimicrobial therapies for oral diseases have been in use for centuries, but have undergone
rapid changes in recent years. New drug-delivery systems for common antimicrobials and novel agents
to modulate the dental plaque/biofilm formation and maturation are currently emerging.2,3 Methods
employed to deliver the antimicrobial agents to the site of oral infection include rinsing, irrigation,
systemic administration and local application using sustained and controlled delivery devices.2,4 The
efficiency of the drug-delivery system designed to target oral infections depends on its ability to deliver
the drug at a bacteriostatic or bactericidal concentration and its ability to retain the medicament long
enough to ensure adequate results. Since local drug delivery in the oral cavity may achieve these
requirements, commercially available formulations such as minocycline microspheres, metronidazole
and minocycline gels, chlorhexidine chips and doxycycline polymers are currently in use to treat
periodontal disease.3–5 In these systems, polymers encapsulating an antibiotic or antiseptic are inserted
or injected into the site of infection, where they degrade and release the active agent at the site of
infection. Although some of these drug-delivery devices may achieve adequate bioavailability of
antimicrobials to the site of infection, there are several disadvantages and limitations with these
systems, as reported previously.3,4 Therefore small molecules with high affinity for enamel and the
ability to deliver antimicrobials directly to the tooth and pellicle surface would be highly desirable.
The selective adsorption of salivary proteins to the tooth surface forms the acquired enamel pellicle.
These salivary molecules include mucins, α-amylase, PRG (proline-rich glycoprotein), PRPs (proline-rich
proteins), cystatins, statherin and histatins. Pellicle-forming salivary proteins have a tooth-enamelbinding domain,6,7 an antimicrobial region7–9 and a region that serves as a receptor for microbial
colonization.10–13 The apatitic/tooth-surface-binding domain and an antimicrobial component could be
linked by a biodegradable bond to efficiently deliver therapeutic agents intra-orally. Such a bifunctional
hybrid molecule is expected to adhere to the tooth and pellicle surfaces uniformly, with a sustained
release of the antimicrobial from the tooth surface inhibiting microbial colonization.
The present paper describes the synthesis of two novel intra-oral antimicrobial delivery molecules, their
substantivity and the antimicrobial release kinetics in clarified human whole saliva, and their toxicity to
human cells. The antimicrobial activity of the molecules adsorbed on the tooth enamel mineral [HAP
(hydroxyapatite)] surface against Candida albicans and Aggregatibacter actinomycetemcomitans,
previously referred to as Actinobacillus actinomycetem-comitans, is also summarized in the present
paper.

EXPERIMENTAL
Selection of peptides

An analogue of the N-terminal fragment of statherin (Asp-Asp-Asp-Glu-Glu) with high affinity for the
enamel surface6 has been selected as the carrier sequence. A 12-residue defensin-like peptide (Arg-LeuCys-Arg-Ile-Val-Val-Ile-Arg-Val-Cys-Arg) with a disulfide bridge between the two cysteine residues was
selected as the antimicrobial, since it has been shown to possess antimicrobial activity against several
oral pathogens.14 The two components were linked through the side chain of a serine/aspartic acid
residue to generate two bifunctional hybrid molecules with an ester and an anhydride bond between
the two components respectively (Figure 1). The Cβ-carbon atoms of the serine and aspartic acid

residues that link the carrier and the antimicrobial were 13C-labelled to monitor the release of the
antimicrobial component from the carrier.

Figure 1 Sequences of hybrid A and hybrid B
The carrier and the antimicrobial components were linked through the side chain of the 13C-enriched amino acid
(serine residue in hybrid A and aspartic acid residue in hybrid B) at the N-terminus of the carrier peptide. In human
saliva, the biodegradable ester and anhydride bonds dissociate, causing a sustained release of the antimicrobial
component.

Among cathelicidins, defensins and histatins that are present in saliva, a defensin-derived peptide was
selected. Defensins are salivary peptides as are histatins, since they are expressed and secreted by the
salivary glands.15,16 Although histatins are potent antifungal peptides, they are antibacterial only at a
much higher concentration than that for defensins.14,17,18 The antimicrobial peptide used in the hybrid
molecule should be compatible in molecular size without hindering the enamel-binding efficacy of the
carrier component. Although cathelicidin LL37 is a potent antimicrobial.19 its much larger size could
mask the structure and function of the carrier molecule. Hence, a 12-residue defensin-like peptide was
selected.

General materials and methods

Chemicals and solvents were of the highest purity available and used without further purification. Amino
acid derivatives, Wang resin and NPN (N-phenyl-1-naphthylamine) were purchased from Sigma and
Bachem. The 13C β-labelled serine and aspartic acid derivatives were purchased from Cambridge Isotope
Laboratories. Calcein-AM (calcein-acetoxymethyl ester) and calcein were obtained from Molecular
Probes. Hybrid peptides were synthesized using an Advanced Chemtech (ACT Model-90) peptide
synthesizer. HPLC was carried out on a Rainin HPXL system interfaced to a Macintosh SE/30 computer,
using a Rainin Dynamax C18 column (10 mm×250 mm) coupled with a guard column (10 mm×50 mm)

and employing an acetonitrile/water (each containing 0.1% trifluoroacetic acid) linear gradient elution
with a flow rate of 2.0 ml/min. The dried peptides were hydrolysed in sealed tubes for 24 h at 110 °C,
using 6 M HCl in the presence of 1% phenol vapour, and amino acid analysis was performed on a
PerkinElmer 420A derivatizer and analyser system. The amino acid sequence of the peptide (∼ 1 nmol)
was checked by sequence analysis, using a PerkinElmer model 477A protein sequencer. FAB (fast atom
bombardment) mass analysis was carried out on a VG Analytical ZAB 2-SE high-field mass spectrometer
(M-Scan). A caesium ion gun was used to generate ions for the acquired spectra, which were recorded
using a PDP 11-250J data system. Fluorescence studies were performed using a PerkinElmer 650-40
fluorescence spectrophotometer. The HAP crystals with a specific surface area of 29±0.3 m2/g
(Brunauer–Emmett–Teller nitrogen adsorption) were prepared as described previously6,20 and
characterized by X-ray powder diffraction (Nicolet/Nic diffractometer with Stoe attachment, using a
position-sensitive detector in the transmission mode). The calcium to phosphate molar ratio in the HAP
crystal was 1.65±0.05.

Synthesis of the bifunctional hybrid molecules (hybrid A and hybrid B)

The synthesis of hybrid A and hybrid B was carried out as outlined in Supplementary Figures 1 and 2
(http://www.BiochemJ.org/bj/409/bj4090601add.htm) by using the standard Fmoc (fluoren-9ylmethoxycarbonyl) and Boc (t-butoxycarbonyl) procedures.14,18,21 The cleaved peptide containing the
acetamidomethyl protecting group on the two cysteine residues was deprotected and oxidized to form
the disulfide, as described previously.14 Hybrid A and hybrid B were purified and tested for homogeneity
as described in the Supplementary data (http://www.BiochemJ.org/bj/409/bj4090601add.htm). The
bond between the carrier and the antimicrobial components was verified by FTIR (Fourier-transform
infrared) spectroscopy. The presence of a disulfide bridge was verified by CD spectroscopy.

Measurements of adsorption on HAP

Adsorption experiments were carried out as described previously.6,22 HAP beads with a specific surface
area of 29.2±0.3 m2/g were used for these experiments. Known amounts of peptides were equilibrated
for 4 h with HAP crystallites (1×103 g) in a saturated solution (1 ml) at 37 °C and pH 7.4, using an ionic
strength of 0.15 mol/l. Adsorption kinetics demonstrated that equilibrium was achieved in less than 4 h.
To avoid bacterial degradation during adsorption, all peptide solutions were prepared with 0.1% 1,1,1trichloro-2-methyl-2-propanol. After adsorption, the HAP crystallites were separated from the
supernatant solution by centrifugation at 250 g for 10 min. The peptide-adsorbed HAP crystallites were
washed with saturated solution of HAP (2×1 ml). The peptide concentration in the supernatant solutions
was determined by amino acid analysis and compared with the initial concentration. Amino acid analysis
indicated that adsorbed molecules on HAP were not removed during washing. A parallel experiment
performed in the absence of HAP crystals showed that peptide adsorption on the reaction vessels was
negligible.

FTIR measurements

ATR-FTIR (attenuated total reflectance FTIR) spectra in solution were recorded on a Bio-Rad FTS-40
spectrometer equipped with a deuterated triglycine sulfate detector and a Bio-Rad 3240-SPC computer
for data acquisition and analysis. Spectra were recorded at 30 °C by using a Micro Circle cell (SpectraTech) with a zinc selenide CIR (cylindrical internal reflectance) crystal in a stainless steel flow cell. A
1024-scan interferogram was collected at a single beam with a resolution of 2 cm−1, using a peptide
concentration of 0.5 mM. The spectrometer was continuously purged with dry air to eliminate water

vapour adsorption. Solvent and sample spectra were recorded under identical conditions, and the
difference spectra were obtained, as described previously.9

CD spectroscopy

CD measurements were carried out to verify the presence of the disulfide bond. An Aviv 62DS
spectropolarimeter equipped with a thermostatic temperature controller and interfaced to an IBM
microcomputer was used. CD spectra were recorded in a quartz cell of 0.05 nm path length at 30 °C,
using a 1.0 nm bandwidth and a scanning rate of 10 nm/min with a wavelength step of 0.2 nm and a
time constant of 2 s. Peptide dissolved in 10 mM sodium phosphate buffer at pH 7.2 at a concentration
of 0.1 mM was used.

NMR studies

All 125-MHz 13C 1D (one-dimensional)-NMR spectra were recorded on a Varian Unity Inova 500 MHz
spectrometer equipped with a SUN Sparckstation 20. A spectral width of 25157.2 Hz, a relaxation delay
of 12 s and an acquisition time of 1.2 s were used. The proton decoupler was on only during the
acquisition time and off during the delay time to eliminate the influence of NOE (nuclear Overhauser
effect) effects on the intensity of the 13C resonances. Thus the signal intensity was dependent only on
the quantity of the material for quantitative estimation.23,24 The 13C -NMR spectra of the hybrid
molecules (500 μM) in 1 ml of clarified human whole saliva containing 5% 2H2O (37 °C, pH 7.2) at various
intervals of time were recorded. Chemical shifts were referenced to tetramethylsilane (Me4Si) in a
concentric capillary.

Selection of test micro-organisms and growth conditions

C. albicans is an opportunistic pathogen and is intimately associated with chronic oral infections which
are increasing in the growing immunocompromised and aging populations worldwide. Moreover, in the
sub-gingival flora of several adult periodontitis and AIDS patients, C. albicans has been detected.22,25 C.
albicans also plays a significant role in DIS (denture-induced stomatitis), which is found in 20% of the
aging population.26 C. albicans infection has been estimated to be as high as 60% among the denturewearing institutionalized subjects.27
Defensins and defensin-like antimicrobial peptide have already been reported to be active against
cariogenic Lactobacillus casei,28 Streptococcus mutans and periodontopathogenic Porphyromonas
gingivalis and A. actinomycetemcomitans.14 To demonstrate and validate the controlled and sustained
antimicrobial release from the hybrid molecules and its activity, C. albicans and A.
actinomycetemcomitans were selected to represent a fungal and a bacterial organism respectively, both
of which are associated with oral infectious diseases.
A clinical isolate of C. albicans strain from a DIS patient was used. The identity of the clinical isolate was
verified by the Yeast System (Flow Laboratories). Organisms were streaked on to Sabouraud Dextrose
Agar plates (Difco) and maintained at 4 °C. One colony of C. albicans from this plate was inoculated into
10 ml of yeast synthetic growth medium containing sucrose, salts and biotin, and incubated for 48 h at
25 °C in a shaker rotating at 200 rev./min to bring yeast cells into the late exponential phase of growth.
The cell morphology was determined by phase-contrast microscopy and found to be uniformly
blastospores. Subcultures were done every 3 days by inoculating 100 μl of 3-day-old culture into 10 ml
of fresh synthetic media.

Candidacidal activity

The candidacidal activity of the hybrid molecules was determined as a function of the release of the
antimicrobial in clarified human whole saliva. The hybrid molecule was incubated with 1 ml of saliva
buffer29 (the composition of which is shown in the Supplementary data) and 4 ml of clarified human
whole saliva such that the final hybrid concentration was 100 μM kept at pH 7.2. The sample was
divided into two and each portion was separately maintained at 37 and −5 °C, the latter to minimize the
dissociation of ester/anhydride bond of the hybrid. Over time, aliquots of both samples (25 μl) were
examined for candidacidal activity, as described previously.8,30 The assays were performed on stationary
C. albicans cells in the presence or absence of the hybrid (25 μl), as described previously.30 Briefly, C.
albicans cells were washed with 10 mM sodium phosphate buffer (pH 7.4) and resuspended at 1.8×105
cells/ml. A cell suspension of 25 μl was mixed with 25 μl of hybrid in saliva and then incubated with
shaking at 37 °C for 1.5 h. Control cultures were incubated with 25 μl of saliva and saliva buffer without
the hybrid peptide. The reaction was stopped by the addition of 360 μl of yeast nitrogen base, and 40 μl
of the suspension was spread on to Sabouraud dextrose agar plates and incubated for 48 h at 37 °C.
Candidacidal assays were performed in duplicate or triplicate. Loss of viability was calculated as {1–
[(number of colonies from suspensions with hybrid)/(number of colonies from suspension with no
hybrid)]}×100.

Measurement of the loss of microbial cell membrane integrity

A. actinomycetemcomitans strain Y4 was maintained on tryptic soy agar plates containing yeast extract
(0.5%). For liquid culture, cells were grown in the respective broths. All experiments were carried out in
an anaerobic chamber (85% N2, 10% H2 and 5% CO2; Coy Laboratory Products) and the purity of the
bacterial strain was confirmed routinely as described previously.7,14
The efficacy of peptides to induce loss of cell membrane integrity has been well correlated with their
microbicidal activity.22,30,31 Hence, the efficacy of the hybrid-bound HAP surface in inducing disruption of
cell membrane permeability was determined as a measure of microbicidal activity. Calcein-AM and NPN
were used as fluorescent probes to examine C. albicans and A. actinomycetemcomitans membrane
permeability respectively. The peptide-induced leakage of a fluorescent probe (calcein-AM)
incorporated within C. albicans membranes, and the peptide-induced incorporation of the membraneexcluded probe (NPN) into bacterial membranes, were monitored.

Measurement of the loss of C. albicans cell membrane integrity

C. albicans cells were loaded with the fluorescent probe calcein-AM. The calcein-AM is non-fluorescent
within the cell. The cellular esterases convert the ester into an acid, the fluorescence of which was
quenched within the cell membrane. The fluorescence was de-quenched when calcein leaks into the
extracellular environment. Peptide-induced leakage of calcein was monitored by measuring the dequenching of fluorescence at 520 nm by exciting the system at 495 nm. The assay was performed as we
described previously.22,30 C. albicans cells (3 days old) were washed twice with 20 ml of PBS and the
concentration was adjusted to 107 cells/ml. Calcein-AM (5 μl of 1 mM) was added to 1 ml of cells. The
cells were incubated for 4 h at room temperature (25 °C) and then washed extensively with 10 mM PBS
to remove unincorporated calcein-AM. For the assay, 100 μl of the calcein-AM-loaded cells (105
cells/ml) were mixed with 50 mg of hybrid-adsorbed HAP beads. The final volume in the cuvette was
1 ml. The fluorescence intensity (Fa) was measured at 520 nm using a λex of 495 nm at regular intervals
of time for 10 h. The cell suspension was stirred gently for 10 s after each measurement and at regular

intervals to ensure cell–bead contact. The fluorescence intensity at 520 nm of cells and clean untreated
HAP beads after 15 min was taken as the background fluorescence (Fb). The total fluorescent content of
the cell was determined by incubating the cells at 100 °C for 5 min (Ft). The minimal non-specific leakage
of fluorescence from cells alone was determined after 6 h and subtracted from that obtained from cells
and hybrid-bound HAP. The percentage release of calcein=[(Fa−Fb)/Ft]×100. The fluorescence intensity
measurement of cells and free HAP beads was used as the control.

Assessment of the loss of bacterial membrane integrity

The membrane permeability induced by the released antimicrobial from the hybrid-adsorbed HAP was
assessed by the extent the antimicrobial permeabilized the outer bacterial membrane. This was
determined by using the neutral hydrophobic probe NPN. Antimicrobial peptides bind to
lipopolysaccharide, displacing the native bivalent cations and disrupting the outer membrane
permeability. NPN is excluded from an intact outer membrane.32,33 However, when the permeability of
the bacterial outer membrane is disrupted, NPN enters the membrane, resulting in fluorescence. Briefly,
1 ml of mid-exponential-phase A. actinomycetemcomitans strain Y4 cell suspension was incubated with
5 μl of 1 mM NPN and then treated with 50 mg of hybrid-bound HAP. Fluorescence intensity was
measured at 420 nm using a λex of 340 nm at regular intervals of time for 10 h. The cell suspension was
stirred gently for 10 s after each measurement and at regular intervals to ensure cell–bead contact. The
percentage intake of NPN was calculated, as described in the previous section, from the formula:
percentage intake of NPN=[(Fa−Fb)/Ft]×100. The fluorescence intensity measurement of cells and free
HAP beads was used as the control.

Isolation of human erythrocytes

The leakage of Hb from human erythrocytes was monitored by using standard procedures.34 Briefly,
blood obtained by venipuncture from normal healthy volunteers with informed consent was collected in
lithium-heparinized tubes, centrifuged at 450 g at 4 °C for short times (5 min), and the plasma and buffy
coat were removed. Erythrocytes were then washed three times with PBS at 4 °C before being dispersed
in PBS, counted in a haemocytometer and used on the day of harvesting. After washing, cells were
resuspended in PBS and adjusted to give a final concentration of 1×108 cells/ml. Ouabain (10−6 M) was
added to the final cell suspension to inhibit the membrane-bound Na+/K+ ATPase pump. For the
determination of leakage of Hb, 2 ml of cell suspension (5×107cells/ml) in PBS was incubated for 1 h at
37 °C with the test material. After the incubation, the cells were centrifuged at 1500 g for 5 min and
washed three times with PBS for 10 s. The supernatant was collected and the degree of haemolysis was
determined by comparing the Hb concentration in the supernatant with that in the original cell
suspension by measuring the absorbance (A) at 540 nm; 0% haemolysis and 100% haemolysis were
determined by suspending cells in PBS and 1% Triton X-100 respectively. Salivary histatin 5 and melittin
were used as negative and positive controls respectively.

Human GEC and GFC culture

Human GECs (gingival epithelial cells) and GFCs (gingival fibroblast cells) were cultured using an explant
technique according to previously described procedures with slight modifications.35,36 Tissue specimens
were derived from histologically normal areas of gingiva collected during elective periodontal/oral
surgical procedures with the consent of otherwise-healthy patients. The GECs were isolated by using
standard procedures.35,37 After collection, gingival tissue specimens were placed in sterile PBS
supplemented with penicillin, streptomycin and amphotericin B. The tissues were then incubated with

0.4% dispase (BM Biochemicals) overnight at room temperature. The surface epithelium was separated,
minced and placed in sterile PBS containing trypsin (0.55%) and EDTA (0.53 mM) to dissociate the intact
epithelium into single cell suspensions. Cells were collected by centrifugation and cultured in serumfree, sterile keratinocyte basal medium supplemented with epidermal growth factor (0.1 ng/ml), insulin
(5 μg/ml), cortisol (0.5 μg/ml), CaCl2 (0.15 mM), bovine pituitary extract (20 μl/ml), gentamicin
(50 μg/ml) and amphotericin B (50 ng/ml) (KGM; Clonetics Corp.). Tissue culture dishes (100 mm) precoated with murine collagen type IV (5 mg/ml) were seeded with stock cultures of cells which had been
stored in liquid nitrogen, and incubated at 37 °C in an air/5% CO2 atmosphere until confluent growth
was attained. Cells were removed from the dishes by trypsin treatment (1×trypsin–EDTA; Fisher
Scientific) for 5 min at room temperature. The cells were harvested by centrifugation at 800 g for 5 min
and resuspended in KGM medium. Cell cultures from the second and third passages were used for
testing. After separating the epithelium, GFCs were cultured by the procedure reported previously.36
Tissues were minced using sterile techniques and washed twice with PBS supplemented with antibiotics
(100 units/ml penicillin, 100 mg of streptomycin and 0.25 μg/ml fungizone). Explants were placed in 60mm Petri dishes and maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v)
FBS (fetal bovine serum) and antibiotics, as described above. Cultures were maintained at 37 °C in a
humidified atmosphere of 5% CO2 and 95% air. Confluent cells were detached by treatment with 0.25%
trypsin and 0.05% EDTA for 5 min, and aliquots of cells were subcultured with the same medium. Cell
cultures from the third to eighth passages were used for investigation.

Cytotoxicity assay

The effect of hybrid molecules on human cells was determined by the colorimetric assay, which is based
on the ability of live but not dead cells to reduce the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2Htetrazolium bromide] to a blue formazan product.38,39 The MTT assay in a 96-well plate was performed
to monitor cell survival and proliferation. MTT assay was carried out by measuring dehydrogenase
activity as described previously,40,41 with minor modifications. Briefly, 1×104 cells per well were seeded
on to a 96-well plate and left overnight. Serial dilution of various extracts (6.25, 12.5, 25, 50 and 75 μl,
prepared in the same solvent) in 100 μl volume was added, and cells were treated for 24 h. After
treatment, 50 μl of MTT solution (1 mg/ml in PBS) was added to each well and incubated for another 4 h
at 37 °C. DMSO (150 μl) was added to each well and the plates were shaken to ensure the dissolution of
crystals. Culture viability was determined by measuring, spectrophotometrically, the reduced MTT in a
dual-beam microtitre plate reader (Molecular Devices tunable microplate reader) at 590 nm with a
630 nm reference. Four wells were used for each experimental group.

RESULTS
Synthesis of hybrid peptides

The synthetic scheme and the purification procedure yielded hybrid A and hybrid B in the pure state
(100%). The percentage yield was 96% with the acetamidomethyl protecting group on the two cysteine
residues. The formation of intra-molecular disulfide between the two cysteine residues was
accomplished in a very dilute solution. After evaporation and purification, the percentage yield of the
final product was 65%.
Analytical HPLC analysis verified the purity of the hybrid peptides. Amino acid analyses were consistent
with the amino acid composition of the respective hybrid molecules. Amino acid sequence analyses

verified the presence of amino acid residues corresponding to the carrier and antimicrobial sequences.
The FAB mass spectra showed intense molecular ion clusters centred at m/z 2275 and 2303 that are
consistent with the molecular masses of hybrid A and hybrid B respectively. The molecular ions are also
consistent with the presence of the disulfide bridge and the 13C β-enriched amino acid residue that
connects the antimicrobial and the carrier components.42,43 The CO stretching band in the FTIR spectra
that occurred between 1725 and 1740 cm−1 verified the presence of an ester bond in hybrid A, whereas
the two bands between 1800 and 1900 cm−1 separated by approx. 65 cm−1 showed the carbonyl stretch
corresponding to the anhydride linkage in hybrid B.44 Hybrid A and hybrid B exhibited a weak negative
n–σ* CD band (Supplementary Figure 3 at http://www.BiochemJ.org/bj/409/bj4090601add.htm) at
approx. 265–270 nm (molar ellipticity≅−5000–6000 deg·cm2·dmol−1), characteristic of the disulfide
bond that is normally observed between 240 and 300 nm.45 Similar CD bands have been observed and
reported for oligopeptides containing a disulfide bridge.8,14,18

Adsorption of hybrid molecules to the HAP surface

The adsorption, Q (mol/m2), of hybrids on the HAP surface measured at various equilibrium
concentrations, C (molar), was determined and compared with that of salivary statherin, as described
previously.46 The affinity coefficient, K (litre/mol), and the maximum number of adsorption sites, N
(mol/m2), calculated by using the Langmuir equation,46 C/Q1=KN+C/N, are provided in Table 1. Hybrid A
and hybrid B exhibited high relative affinity for HAP with the K values of 9.0±1.8 and 9.2±1.7 litres/mol
respectively (Table 1). The extent of adsorption on HAP and the affinity coefficients were quite
comparable with those of salivary statherin (Table 1), which has been reported to have the highest
affinity for the HAP surface.6 The affinity coefficient K (litre/mol), and the maximum number of
adsorption sites, N (mol/m2), observed for salivary statherin (Table 1) were consistent with those
reported previously.6,20 Affinity coefficient values observed for hybrid A and hybrid B suggested that
both the molecules could efficiently bind to the tooth enamel mineral surface. Even though salivary
statherin and the hybrid molecules have comparable affinity coefficients, hybrid A and hybrid B showed
a higher maximum adsorption, suggesting that a greater number of smaller molecules were able to
interact per unit surface area of HAP than the longer parent molecule. The antimicrobial at the Nterminus of the carrier did not seem to alter the affinity for HAP surface.
Table 1 Langmuir parameters for salivary statherin and hybrid molecules
K and N values observed for salivary statherin are consistent with those reported previously.6,20
Peptide
K×10−6 (litre/mol) N×106 (mol/m2)
Statherin
11.2±1.1
0.44±0.1
Hybrid A
9.0±1.8
1.9±0.1
Hybrid B
9.2±1.7
2.0±0.2

The adsorption of salivary statherin and its fragments on HAP mineral is a real equilibrium system as
reported previously.6,20 As mentioned in the Experimental section, previous adsorption experiments
showed that equilibrium was achieved in less than 4 h.6,20 The susceptibility of the ester and anhydride
linkages in hybrid A and hybrid B respectively could influence the equilibrium. However, 13C -NMR data
reported in the present paper suggested that the dissociation of the hybrid was slow and expected to be
minimal within 4 h. Hence, the affinity constant values determined were well within the error limits.

Kinetics of the antimicrobial release in human whole saliva

The Cβ-carbon atoms of the serine and aspartic acid residues that connected the carrier and the
antimicrobial in hybrid A and hybrid B respectively were enriched with 13C to monitor the release of the
antimicrobial by 13C -NMR spectroscopy. Since the natural abundance of 13C is only 1.1%, the resonance
intensities of all other carbons merged with the noise levels except the 13C β-carbons of the 13C -enriched
serine and aspartic acid residues. The integrated intensity of the 13C β resonances was monitored to
determine the extent of release of the antimicrobial in saliva. Quantitative estimation of molecules
based on the integrated intensity of 13C resonance has been well documented.23,24 The 13C -NMR spectra
of hybrid A and hybrid B (each 500 μM) in clarified human whole saliva recorded at 37 °C and pH 7.2 at
various intervals of time are provided in the Supplementary data. As described in the Supplementary
data, the integrated intensity of CβH2OH and CβH2COOH over time was used to determine the kinetics of
release of the antimicrobial from hybrid A and hybrid B respectively (see Supplementary Figure 4 at
http://www.BiochemJ.org/bj/409/bj4090601add.htm). As described in Figure 2(A), the increase in the
integrated intensity of CβH2OH plotted over time suggested that 50% of hybrid A dissociated in clarified
human whole saliva over a period of 32 h, indicating that a sustained release of the antimicrobial could
be achieved over a period of more than 60 h. The increase in the integrated intensity of CβH2COOH over
time suggested that 50% of hybrid B dissociated over a period of 20 h (Figure 2A), indicating that the
antimicrobial could be released in saliva over a period of 40 h. The results suggested that in clarified
human whole saliva, hybrid A and hybrid B could substantially release the antimicrobial over a period of
60 and 40 h respectively. Under similar conditions, the anhydride linkage between the carrier and the
antimicrobial released the antimicrobial faster than the ester bond in hybrid A (Figure 2A).

Figure 2 Kinetics of the release of the antimicrobial from the carrier

(A) The dissociation of the ester and anhydride bonds in hybrid A and hybrid B respectively as determined by the
increase in the integrated intensity of the 13C resonances of CβH2OH and CβH2COOH in hybrid A and hybrid B
respectively over time. Peptides (500 μM) were dissolved in 1 ml of human clarified whole saliva containing 5%
2
H2O at 37 °C and pH 7.2. (B) Percentage loss of viability of C. albicans (DIS) induced by hybrid A and hybrid B in
clarified human whole saliva maintained at −5 °C and at 37 °C over time. Hybrid molecules were dissolved in 1 ml
of saliva buffer and 3 ml of clarified human whole saliva (at pH 7.2 and a peptide concentration of 100 μM).
Samples were maintained separately at 37 and −5 °C. Aliquots were examined for candidacidal activity over time as
described in the Experimental section. Results are means±S.D. for duplicate determinations from three different
experiments.

Candidacidal activity of hybrid molecules as a function of the antimicrobial release

The candidacidal activity of hybrid A and hybrid B in clarified human whole saliva (100 μM) maintained
at 37 °C and −5 °C is provided in Figure 2(B). The loss of cell viability of the hybrid molecules maintained

at 37 °C was found to be approx. 20% at the initial time (Figure 2B). This might be due to the intact
hybrid molecule. The increase in the candidacidal activity was not significant for up to nearly 1 h. After
this period, the percentage loss of viable cells increased over time, and 90% killing was achieved within
5 h for hybrid A (Figure 2B) and 3 h for hybrid B. However, for samples maintained at −5 °C, the
percentage loss of viable cells did not increase with time, suggesting that the dissociation of the hybrid
molecules was minimal at low temperature and reflected the activity of the intact molecule, since the
dissociation of the ester and anhydride bonds was expected to be minimal at this temperature. The
results suggested that hybrid A and hybrid B released the antimicrobial over time in human saliva at
37 °C and enhanced the candidacidal activity (Figure 2B). The increase in the candidacidal activity over
time was consistent with the 13C -NMR data and the kinetics of the release of the antimicrobial from the
hybrid molecules (Figure 2A).

Candidacidal activity of the hybrid-adsorbed HAP surface

Hybrid-adsorbed HAP beads obtained by equilibration with the hybrid concentration (4.0×10−5 mol/l)
were used to determine the candidacidal activity of peptides in a bound state on the mineral surface.
Incubation of calcein-AM-loaded C. albicans with the hybrid-adsorbed HAP beads caused a steady
increase in fluorescence intensity over time measured at 520 nm, when excited at 490 nm. The increase
in fluorescence intensity was measured and the percentage release of the fluorescent probe from the C.
albicans membrane over time is shown in Figure 3(A). The increase in fluorescence intensity was not
significant for 0.5 h. After this time, a steady significant enhancement in fluorescence intensity was
observed for hybrid A- and hybrid B-adsorbed HAP surfaces, as compared with that of the free HAP
beads (Figure 3A). The result suggested the leakage of the fluorescent probe calcein-AM from C. albicans
membrane, as a consequence of the increased membrane permeability and the damage caused by the
antimicrobial component of the hybrid molecules. Collectively, the results suggested that the
antimicrobial component of the hybrid was released over time from the HAP surface disrupting the C.
albicans membrane.

Figure 3 Candidacidal activity of hybrid-molecule-adsorbed HAP surface

(A) Candidacidal activity as determined by the percentage release of calcein from C. albicans membrane. Calcein
release induced by the antimicrobial released from (a) hybrid A-adsorbed HAP surface, (b) hybrid B-adsorbed HAP
surface and (c) control HAP surface. (B) Bactericidal activity of hybrid-molecule-adsorbed HAP surfaces as
determined from the percentage intake of NPN into A. actinomycetemcomitans cell membrane. The percentage
intake of NPN induced by the antimicrobial released from (a) hybrid A-adsorbed HAP surface, (b) hybrid Badsorbed HAP surface and (c) control HAP surfaces. Experiments were carried out at 37 °C and pH 7.2. Results are
means±S.D. for duplicate determinations from three different experiments.

Bactericidal activity of the hybrid-adsorbed HAP surface

Hybrid-adsorbed HAP beads were also used to determine the bactericidal activity against A.
actinomycetemcomitans. The efficacy of the antimicrobial component of the hybrid to permeabilize the
bacterial membrane was determined by using the fluorescent probe NPN. Incubation of A.
actinomycetemcomitans cells with the hybrid-adsorbed HAP resulted in an increased fluorescence over
time. The increase in fluorescence intensity was found to be slow for the initial 0.5 h. After this period, a
steady increase in fluorescence was observed over time for HAP surfaces coated with hybrid A and
hybrid B. The percentage intake of NPN into the bacterial membrane calculated from the fluorescence
intensity over time is shown in Figure 3(B). As compared with the control HAP, which has no hybrid on
its surface, hybrid A- and hybrid B-adsorbed HAP surfaces showed a significant increase in the
percentage intake of NPN (Figure 3B). The result suggested the incorporation of NPN into the bacterial
membrane due to increased membrane permeability caused by the antimicrobial component released
from the respective HAP surface. Collectively, the results suggested that the antimicrobial component of
the hybrid was released over time from the HAP surface causing the A. actinomycetemcomitans cell
membrane to permeabilize (Figure 3B).

Hybrid-induced leakage of Hb

The percentage release of Hb as a function of molar concentration of peptides is described in Figure 4.
Hybrid A and hybrid B exhibited minimal haemolysis over the concentration range of 0–250 μM,
suggesting that these molecules did not permeabilize human erythrocytes, although they exhibited
marked influence on microbial cell membranes. Melittin is known to permeabilize human erythrocytes
and it exhibited a significant increase in percentage haemolysis (Figure 4). Salivary histatin 5, which is
expected to be non-toxic, appeared to exhibit some haemolytic activity at a high concentration.
However, the hybrid molecules did not affect human erythrocyte membrane up to a concentration of
250 μM.

Figure 4 Effect of hybrid molecules on human erythrocytes
The leakage of Hb was determined by measuring the absorbance at 540 nm. The percentage haemolysis was
determined at 37 °C for various peptide concentrations; 0% haemolysis and 100% haemolysis were determined by
suspending the cells in PBS and 1% Triton X-100 respectively. Salivary histatin 5 and melittin were used as the
negative and positive controls respectively. Results are means±S.D. for duplicate determinations from three
different experiments.

Effects of hybrids on human GECs and GFCs

The MTT assay was used to determine the viability and proliferation of human GECs and GFCs. When
these cells were exposed to hybrid A or hybrid B (at 62.5 and 250 μM), the effects on cell viability and
proliferation over time are described in Figure 5. Chlorhexidine, which is currently used as the gold
standard for oral antiseptics, was examined as the positive control. Even at the concentration of
250 μM, neither of the hybrid molecules affected cell viability over a period of more than 72 h. In
addition, cell proliferation was not affected by the presence of the hybrid molecules (Figure 5). On the
other hand, even at a much lower concentration (125 μM), cell viability and growth were significantly
affected, when human GECs and GFCs were exposed to chlorhexidine which was consistent with
previous reports.47,48 The results suggested that hybrid A and hybrid B are not toxic to human GECs and
GFCs.

Figure 5 Effect of hybrid molecules on human GECs and GFCs

Hybrid molecules' effect on human GECs (A) and human GFCs (B). Cell viability and proliferation were monitored
over time using the MTT assay, as described in the Experimental section by measuring spectrophotometrically the
reduced MTT in a dual-beam microtitre plate reader at 570 nm with a 650 nm reference. The effect of the
presence of (a) the culture medium (control), (b) chlorhexidine, (c) hybrid A at 62.5 μM, (d) hybrid A at 250 μM, (e)
hybrid B at 62.5 μM (f) or hybrid B at 250 μM on cell viability and proliferation is shown.

DISCUSSION
Tooth enamel-binding peptides as carriers for intra-oral delivery of therapeutics

The fragment (Asp-Asp-Asp-Glu-Glu) of statherin could be used as a carrier for intra-oral delivery of
therapeutic agents. The oral physiological environment could greatly induce the release of the
antimicrobial from the tooth surface and in saliva due to the susceptibility of the ester and anhydride
bonds. In salivary defence molecules, the antimicrobial sequences are linked by the secondary
amide/peptide bond and the release of the antimicrobial requires specific salivary proteolysis. However,
microbial invasion results in the inactivation of salivary proteolysis and the secretion of natural
antimicrobials.49 Therefore, it becomes necessary to deliver antimicrobials intra-orally and to induce a
sustained release of the antimicrobial from the tooth surface and in saliva. The ester/anhydride bond in
the hybrid might cause a sustained release of the antimicrobial over time without the involvement of
any specific enzyme.
Molecules designed to target oral pathogens should be stable in saliva and the antimicrobial component
should be released gradually over time to combat microbial colonization. Hybrid A and hybrid B
appeared to meet these criteria in vitro, as described in the 13C -NMR studies (Figure 2A) The high
affinity coefficients observed for hybrid A and hybrid B (Table 1) indicated that they could be
substantially adsorbed on the tooth surface when used topically as a mouth rinse. Hybrid molecules did
not appear to be toxic to human cells, including human erythrocytes (Figures 4 and 5).

Intra-oral delivery of antimicrobials

Caries, gingivitis and periodontal disease still remain the most common infections in humans. The major
limitations of the currently available local drug-delivery systems include: (i) adverse events such as
dental or gingival pain, soreness, discomfort and sensitivity; (ii) difficulty in inserting or injecting the
drug-delivery device around all teeth; (iii) retention of the device at the tooth surface or within the
periodontal pockets for a sufficient length of time; (iv) toxic effects and bacterial resistance induced by
the conventional antibiotics used in the current devices; and (v) requirement for professional application
and high cost.2–4 In contrast with the existing formulations that have little to no affinity for the tooth or

pellicle surface, the bifunctional hybrid molecules could adhere on the tooth and pellicle surfaces
uniformly due to the high affinity for the tooth enamel surface, thereby inhibiting microbial
accumulation. In addition, these bifunctional molecules would decrease the limitations and discomfort
associated with the currently available local drug-delivery devices.
These two bifunctional hybrid molecules could serve as efficient intra-oral antimicrobial delivery
systems that may: (i) get adsorbed quickly with high affinity on the tooth and pellicle surfaces; (ii)
provide a sustained release of an antimicrobial induced by the oral physiological environment; (iii) block
the binding sites on tooth and pellicle surfaces to inhibit bacterial recolonization promoted by the
adsorbed salivary proteins; (iv) disrupt bacterial cell membranes leading to cell death due to the
presence of the selective natural antimicrobial agent, thereby reducing drug resistance among oral
pathogens, and (v) eliminate the discomfort and other disadvantages of the currently available drugdelivery devices. Unlike the local delivery devices that require professional insertion or injection, the
hybrids can be easily applied and replenished by rinsing, brushing or irrigation. They could also be used
professionally for site-specific applications to sub-gingival areas, if required.
Although new drug-delivery systems such as nanoparticles, microbubbles, mucoadhesives and hydrogels
have emerged in recent years, they have not yet been fully developed for intra-oral delivery of
antimicrobials.3 The results presented in the present paper demonstrate the proof of concept for a novel
intra-oral delivery system and validate the previously proposed defence mechanism that exists in the
oral cavity.7,13 However, further studies are required to validate the in vivo efficacy of intra-oral
antimicrobial delivery and safety of these hybrid peptides.
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